Literature DB >> 11555643

Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides.

X Xu1, F Hamhouyia, S D Thomas, T J Burke, A C Girvan, W G McGregor, J O Trent, D M Miller, P J Bates.   

Abstract

The discovery of G-rich oligonucleotides (GROs) that have non-antisense antiproliferative activity against a number of cancer cell lines has been recently described. This biological activity of GROs was found to be associated with their ability to form stable G-quartet-containing structures and their binding to a specific cellular protein, most likely nucleolin (Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. (1999) J. Biol. Chem. 274, 26369-26377). In this report, we further investigate the novel mechanism of GRO activity by examining their effects on cell cycle progression and on nucleic acid and protein biosynthesis. Cell cycle analysis of several tumor cell lines showed that cells accumulate in S phase in response to treatment with an active GRO. Analysis of 5-bromodeoxyuridine incorporation by these cells indicated the absence of de novo DNA synthesis, suggesting an arrest of the cell cycle predominantly in S phase. At the same time point, RNA and protein synthesis were found to be ongoing, indicating that arrest of DNA replication is a primary event in GRO-mediated inhibition of proliferation. This specific blockade of DNA replication eventually resulted in altered cell morphology and induction of apoptosis. To characterize further GRO-mediated inhibition of DNA replication, we used an in vitro assay based on replication of SV40 DNA. GROs were found to be capable of inhibiting DNA replication in the in vitro assay, and this activity was correlated to their antiproliferative effects. Furthermore, the effect of GROs on DNA replication in this assay was related to their inhibition of SV40 large T antigen helicase activity. The data presented suggest that the antiproliferative activity of GROs is a direct result of their inhibition of DNA replication, which may result from modulation of a replicative helicase activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555643     DOI: 10.1074/jbc.M104446200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Bidirectional DNA unwinding by a ternary complex of T antigen, nucleolin and topoisomerase I.

Authors:  Stephanie Seinsoth; Heike Uhlmann-Schiffler; Hans Stahl
Journal:  EMBO Rep       Date:  2003-03       Impact factor: 8.807

2.  A nucleolin-binding 3' untranslated region element stabilizes beta-globin mRNA in vivo.

Authors:  Yong Jiang; Xiang-Sheng Xu; J Eric Russell
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 3.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 4.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

5.  DNA Walker-Regulated Cancer Cell Growth Inhibition.

Authors:  Feiran Li; Tae-Gon Cha; Jing Pan; Altug Ozcelikkale; Bumsoo Han; Jong Hyun Choi
Journal:  Chembiochem       Date:  2016-04-28       Impact factor: 3.164

6.  Biophysical and biological properties of quadruplex oligodeoxyribonucleotides.

Authors:  Virna Dapić; Vedra Abdomerović; Rachel Marrington; Jemma Peberdy; Alison Rodger; John O Trent; Paula J Bates
Journal:  Nucleic Acids Res       Date:  2003-04-15       Impact factor: 16.971

7.  PNAS-4, an Early DNA Damage Response Gene, Induces S Phase Arrest and Apoptosis by Activating Checkpoint Kinases in Lung Cancer Cells.

Authors:  Zhu Yuan; Wenhao Guo; Jun Yang; Lei Li; Meiliang Wang; Yi Lei; Yang Wan; Xinyu Zhao; Na Luo; Ping Cheng; Xinyu Liu; Chunlai Nie; Yong Peng; Aiping Tong; Yuquan Wei
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 8.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 9.  Structure-based drug design: from nucleic acid to membrane protein targets.

Authors:  Magdalena M Dailey; Chayanendu Hait; Patrick A Holt; Jon M Maguire; Jason B Meier; M Clarke Miller; Luigi Petraccone; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

10.  Structure-function analysis of nucleolin and ErbB receptors interactions.

Authors:  Keren Farin; Ayelet Di Segni; Adam Mor; Ronit Pinkas-Kramarski
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.